##### 



---

---

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-K/A

(X Box)     ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2001

OR

(Box)     TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Commission file number: 0-12042

BIOGEN, INC.

(Exact name of Registrant as specified in its charter)


|                                                                             |  |  |  |                                                
|---------------------------------------------------------------------------- |  |  |  | -----------------------------------------------
|Massachusetts
(State or other jurisdiction
of incorporation or organization) |  |  |  | 04-3002117
(I.R.S. Employer
Identification No.)

14 Cambridge Center, Cambridge, Massachusetts 02142
(Address of principal executive offices) (zip code)

Registrants telephone number, including area code: (617) 679-2000

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $.01 par value
(Title of class)

Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.

Yes    (X Box)     No    (Box)

Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to
the best of Registrants knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K.   (X Box)

Aggregate market value of Common Stock held by non-affiliates of the
Registrant at March 26, 2002 (excludes shares held by affiliates):
$7,324,113,016. Exclusion of shares held by any person should not be construed
to indicate that such person possesses the power, direct or indirect, to direct
or cause the direction of management or policies of the Registrant, or that
such person is controlled by or under common control with the Registrant.
Common Stock outstanding at March 26, 2002: 148,511,993 shares.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrants definitive Proxy Statement for its 2002 Annual
Meeting of Stockholders are incorporated by reference into Part III of this
Report, and portions of the Registrants 2001 Annual Report to Shareholders are
incorporated by reference into Parts II and IV of this Report.





---



##### 



This form 10-K/A amends the Companys Annual Report on Form 10-K for the
fiscal year ended December 31, 2001 to add as exhibits to the Form 10-K the
financial statements for the Biogen Savings Plan and the related independent
accountants consent.

PART IV

ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K

(3)  Exhibits

The following documents are added as exhibits to the Form 10-K:

|            |  |                                             
|----------- |  | --------------------------------------------
|EXHIBIT NO. |  | DESCRIPTION                                 
|           
|           
|           
|           
|(23)        |  | Consent of PricewaterhouseCoopers LLP       
|           
|           
|           
|           
|            |  |                                             
|           
|           
|           
|           
|(99.1)      |  | Financial Statements for Biogen Savings Plan

Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.

|             |  |                                                                                                       |  | 
|------------ |  | ----------------------------------------------------------------------------------------------------- |  | 
|BIOGEN, INC. |  |                                                                                                      
|            
|            
|            
|            
|             |  |                                                                                                       |  | 
|            
|            
|            
|            
|By:          |  | /s/ Peter N. Kellogg

Peter N. Kellogg
Executive Vice President  Finance and
Chief Financial Officer |  | 

Dated June 28, 2002